Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.

British journal of clinical pharmacology - 1 Apr 2013

Johnson Daniel H, Gebretsadik Tebeb, Shintani Ayumi, Mayo Gail, Acosta Edward P, Stein C Michael, Haas David W

Abstract excerpt

AIMS: To determine pharmacokinetic and pharmacogenomic correlates of efavirenz central nervous system (CNS) side effects following a single dose. METHODS: Thirty-four healthy HIV-negative African Americans were administered a 600 mg dose of efavirenz. Blood samples for pharmacokinetics were drawn serially from 0 to 12 h post-dose. Neuropsychometric testing with drowsiness visual analogue scale, grooved pegboard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Alkynes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Benzoxazines

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Oxidoreductases, N-Demethylating

Share to Psychomotor Performance

Source

Open in PubMed Open full text

Identifiers

PMID: 22957905
DOI: 10.1111/j.1365-2125.2012.04454.x
PMCID: PMC3612718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.PMID 22957905Read ↗

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.Semantic proximity Read ↗

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).Semantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Semantic proximity Read ↗

Efavirenz and the CNS: what we already know and questions that need to be answered.Semantic proximity Read ↗

Impact of pharmacogenetics on CNS side effects related to efavirenz.Semantic proximity Read ↗

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.Semantic proximity Read ↗

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Semantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Semantic proximity Read ↗

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.